All articles tagged with #ovarian cancer
A 19-year-old from Caernarfon, Enlli Thompson, was diagnosed with stage 3 ovarian cancer after years of misattributed symptoms; she had a hysterectomy that caused immediate menopause and ended her fertility, but she froze seven eggs before chemotherapy and is now navigating menopause while campaigning for awareness and pursuing a career in cancer care.
A Nature Aging study shows fructose secreted by chemotherapy‑induced senescent ovarian cancer cells acts as a signaling molecule that reduces cell adhesion and promotes detachment and metastasis in cell cultures and mice; altering fructose metabolism blocked movement, and high-fructose intake worsened spread in animals, suggesting dietary fructose restriction and senolytic therapies could improve treatment outcomes—though findings are preclinical and not yet applicable to humans.
Researchers at The Wistar Institute found that fructose released by treatment-surviving ovarian cancer cells acts as a signal that weakens cell–cell adhesion and promotes detachment and spread. The effect can occur even without chemotherapy, and higher dietary fructose may influence tumor behavior, with cholesterol-lowering statins also weakening cancer cell adhesion. The study, published in Nature Aging, raises the possibility that this mechanism could occur in other torso-spreading cancers, though clinical studies are needed.
Researchers at The Wistar Institute report that fructose released by chemotherapy-surviving ovarian cancer cells acts as a signal to neighboring tumor cells, promoting detachment and metastatic spread. In preclinical tests, high dietary fructose could enhance cancer spread by lowering cholesterol production in nearby cells, weakening cell adhesion; the finding also suggests interactions with cholesterol-lowering drugs (statins). While intriguing, these effects have not been tested in patients, and researchers caution against changing medications yet. More studies are planned to see if this pathway affects other cancers and whether diet or statin use could influence outcomes.
A new study finds the sugar fructose produced by chemotherapy-surviving tumor cells can signal neighboring cancer cells to spread, potentially affecting ovarian cancer progression and raising questions about diet and statin interactions. The findings are preclinical and suggest nutrition could influence cancer progression, but more research is needed before changing patient care.
Johnson & Johnson has set aside up to $5.5 billion to resolve about 76,000 US lawsuits alleging its talcum powder products caused ovarian cancer, offering plaintiffs up to $3 billion in 2027 with any remaining payouts after 2028; the deal would require acceptance by at least 95% of the claimants’ law firms to proceed. The company has faced decades of talc litigation, has defended the safety of its products, and has already shifted away from talc-based powder in North America (2020) and worldwide (2023).
Johnson & Johnson proposes a $5.5 billion talc settlement to resolve remaining lawsuits alleging its talc caused ovarian cancer, contingent on at least 95% claimant participation, with an initial up-to-$3 billion payment next year and no further payments until 2028, after ongoing courts and prior settlements shaped the case.
A Nature Metabolism study shows lipids in ovarian cancer ascites rewire T cell membranes and metabolism, notably 18:0–18:2 phosphatidylcholine, which impairs T cell activation by disrupting nanoscale TCR clustering in the immunological synapse. These lipids alter membrane order and TCR recycling, reducing activation at physiological concentrations; pre-activated T cells can overcome the barrier, pointing to strategies to improve adoptive T cell therapies for ovarian cancer.
Oncologists warn talc-based powders (used in baby and body powders) may carry cancer risk due to asbestos contamination in talc deposits; the World Health Organization classifies asbestos-contaminated talc as carcinogenic. While not all talc causes cancer, exposure from mining near asbestos raises concerns, so experts urge ditching talc-based powders and opting for safer alternatives like cornstarch, arrowroot, or rice starch; there is no known safe dose for talc-based powders.
Tennis legend Chris Evert revealed that her ovarian cancer has returned and she will undergo surgery and chemotherapy, forcing her to skip ESPN Wimbledon coverage and step back from professional duties to focus on treatment; she previously beat the disease in 2022 and 2023, and a Netflix documentary about her and Martina Navratilova's cancer battles is releasing.
Tennis great Chris Evert, 71, announced that her ovarian cancer has returned for a third time after recent CT and PET scans. She has already undergone surgery and will begin chemotherapy in the coming weeks, stepping back from ESPN Wimbledon coverage to focus on treatment. Evert previously battled ovarian cancer in 2021 and 2023 and beat it both times; her news comes just as Netflix releases a documentary about her and Martina Navratilova, Chris & Martina: The Final Set.
Former Wimbledon champion Chris Evert, 71, says her ovarian cancer has returned for a third time. After CT and PET scans, she underwent surgery and will begin chemotherapy in the coming weeks, forcing her to miss Wimbledon and step back from broadcasting duties to focus on treatment; she remains optimistic and grateful for support as she fights the disease.
A Welsh woman believes she might have avoided ovarian cancer if Wales had offered BRCA genetic testing in 2014 like England did for under-50 women with triple-negative breast cancer; she only discovered her BRCA1 mutation after an ovarian cancer diagnosis in 2021, highlighting cross-border and regional disparities in access to testing and screening that Wales says it is addressing in a new cancer plan.
A mother of three endured years of dismissed symptoms before a female doctor finally recognised something was wrong and diagnosed Stage 4b low-grade serous ovarian cancer (LGSOC). She underwent extensive surgery and chemotherapy, later achieving remission and now campaigns to raise awareness of LGSOC and the dangers of dismissing women's health concerns, particularly around World Ovarian Cancer Day.
A new targeted ovarian cancer drug, mirvetuximab soravtansine, is now funded by the NHS for patients whose tumors express folate receptor alpha, delivering chemotherapy directly to cancer cells, reducing side effects and extending average survival from 12.8 to 16.5 months, potentially benefiting up to 400 patients a year in England.